Performance and Safety of MEX-CD1 Low-volume Continuous Veno-venous Haemodialysis Medical Device for Copper-extraction in Patients With Wilson's Disease (MEXWILS)

MEXWILS - Performance and Safety of MEX-CD1 Low-volume Continuous Veno-venous Haemodialysis Medical Device for Copper-extraction in Patients With Wilson's Disease

The goal of this clinical trial is to test the MEX-CD1 hemodialysis medical device in patients suffering from Wilson's Disease. The main questions it aims to answer are:

• Does the device work as expected by removing the excess of free copper from the blood?
• Is the device safe when used according to the instructions for use?

Depending on the severity of their symptoms, patients will receive either 5 or 10 treatments on consecutive days with the MEX-CD1 hemodialysis medical device.

Study Overview

• Status: Terminated
• Conditions: Hepatolenticular Degeneration; Wilson
• Intervention / Treatment: Device: Low-volume continuous veno-venous haemodialysis

Detailed Description

This study investigates the performance and safety of the MEX-CD1 hemodialysis device in patients suffering from Wilson's Disease. Wilson's Disease is a rare genetic disease (1'000 to 2'000 patients in France) linked to a problem in copper homeostasis. The direct consequence is a progressive accumulation of copper, first in the liver and then in the whole body with two major implications: (i) at the hepatic level and (ii) at the neurological level.

The disease is globally well known and managed in developed countries. It can present itself in several manners:

An acute decompensation of the disease is possible. This concerns mainly big children or young adults, presenting themselves with an acute hepatic deficiency that may need intensive care and a liver transplant.

In most cases, the clinical picture is one of chronic hepatic and/or neurological disease. Treatment must be adapted to the clinical situation. Two phases can be distinguished:

• A primary treatment phase, whose goal it is to eliminate the excess copper deposited in the body. This phase generally takes 1 to 2 years with chelating treatments;
• A maintenance phase, corresponding to the treatment which will allow the copper balance to be maintained and equilibrated.

This lifelong treatment is to be taken daily (with doses of chelators and/or zinc salts).

Finally, during the maintenance phase, periods of lesser observance or escape phases can be observed, those are responsible for severe aggravation of the liver (fulminant hepatitis) or of neurological symptoms that can lead to death.

The proposed medical device allows, by combining dialysis to a hyper-chelating colloidal dialysate (MEX-CD1) to specifically extract copper from the blood (and particularly the exchangeable copper). All patients enrolled in this study will, depending on the severity of their symptoms, receive 4-hour long treatments with MEX-CD1:

• Patients with moderate liver injury not requiring extracorporeal blood epuration therapies as standard of care: 5 treatments with MEX-CD1 on consecutive days
• Patients requiring extracorporeal blood epuration therapies as standard of care: 10 treatments with MEX-CD1 on consecutive days During the MEX-CD1 treatment, the patient's condition will be closely monitored. Additionally, enrolled patients will have a thorough assessment of their Wilson's Disease at the screening visit and at the last visit. Between the last day of treatment and the last visit, enrolled patients will have two rest days.

• Study Type: Interventional
• Enrollment (Actual): 1
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Auvergne-Rhône-Alpes
    • Bron, Auvergne-Rhône-Alpes, France, 69500
      • Hôpital Femme Mère Enfant, Service des urgences et la réanimation pédiatriques
    • Lyon, Auvergne-Rhône-Alpes, France, 69317
      • Hôpital Croix Rousse, Service d'hépatologie et gastroentérologie
• Spain
  • Catalonia
    • Barcelona, Catalonia, Spain, 08035
      • Hospital Universitario Vall d'Hebron, Unitat de Trasplantament Hepàtic Pediàtric
    • Barcelona, Catalonia, Spain, 08036
      • Hospital Clinic Barcelona, Liver ICU

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Males and females aged between 10 years and 80 years and weighing 30 kg and more
• Established diagnosis of Wilson disease (current Leipzig score ≥ 4). (For patients to whom Leipzig score can't be calculated at time of screening (while waiting for the genetic results), we assume a score of 4 (mutation detected on 2 chromosomes by default) if the two parents are Wilsonian.
• Adequate venous access to allow the setting up of recirculated low-volume continuous veno-venous hemodialysis (dialysis catheter ≥11.5 F, medium blood flow rate 100-200 mL/min) and the collection of blood samples.
• Both the patients already under Standard Of Care (SOC) or not under SOC.
• Patients must present at least one moderate hepatic or Neuropsychiatric symptom(s). (please refer 3.4 for the severity criteria)
• Patient, or parent or guardian in the case of minor, must have been informed about the nature of the clinical investigation, and must have agreed to participate in the clinical investigation, and signed the Informed Consent Form (ICF) prior to participation in any clinical investigation-related activities. Minors under the age of 14 must provide oral consent to participate in the clinical investigation.

Exclusion Criteria:

• Males and females weighing less than 30 kg
• Patients suffering from copper deficiency
• Patients who are unwilling or unable to comply with clinical investigation procedures
• Seafood allergy and prior allergy to one of the MEX-CD1 product components
• Allergy or contraindication to heparin or citrate
• Inadequate venous access
• Participation in another investigation with an investigational drug or another Medical Device (MD) within 30 days preceding, and during the present investigation
• Pregnant or breastfeeding women according to Article 66 of the Regulations (EU) 2017/745 on Medical Devices

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: MEX-CD1 Low volume CVVHD; Patients enrolled in the treatment arm will receive MEX-CD1 treatment depending on the severity of their symptoms in addition to standard of care: Patients with moderate liver injury not requiring extracorporeal blood epuration therapies as standard of care: 5 treatments with MEX-CD1 on consecutive days; Patients requiring extracorporeal blood epuration therapies as standard of care: 10 treatments with MEX-CD1 on consecutive days

Device: Low-volume continuous veno-venous haemodialysis; MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. One treatment will last 4 hours. For non-hospitalized patients, the treatment is performed on an outpatient basis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Performance of MEX-CD1	The primary objective is to determine the performance of MEX-CD1 in terms of copper extraction in low-volume continuous veno-venous hemodialysis. This will be measured by the mean net amount of copper extracted per unit time relative to baseline, i.e., a proportion.	4 hours; from treatment start (0 hours) to treatment end (4 hours)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulse measurement for safety purposes	Assessment of the safety of the MEX-CD1 medical device in low-volume continuous veno-venous hemodialysis. Safety end point measurements are evaluated throughout the study.	From the start of the first MEX-CD1 treatment until the last visit, assessed up to 2 weeks.
Temperature measurement for safety purposes	Assessment of the safety of the MEX-CD1 medical device in low-volume continuous veno-venous hemodialysis. Safety end point measurements are evaluated throughout the study.	From the start of the first MEX-CD1 treatment until the last visit, assessed up to 2 weeks.
Arterial blood pressure measurement every hour during treatment phase for safety purposes	Assessment of the safety of the MEX-CD1 medical device in low-volume continuous veno-venous hemodialysis. Safety end point measurements are evaluated throughout the study.	Once at screening and last visit and every hour during treatment phase, assessed up to 2 weeks.
Weight measurement for Safety purposes	Assessment of the safety of the MEX-CD1 medical device in low-volume continuous veno-venous hemodialysis. Safety end point measurements are evaluated throughout the study. Weight measurement before and after each treatment.	From the start of the first MEX-CD1 treatment until the last visit, assessed up to 2 weeks.
AE recording	Assessment of the safety of the MEX-CD1 medical device in low-volume continuous veno-venous hemodialysis. Safety end point measurements are evaluated throughout the study.	From the start of the first MEX-CD1 treatment until the last visit, assessed up to 2 weeks.
Number of participants with abnormal laboratory test results	Safety measurements via blood sample analysis before and after each 4-hour dialysis session	From the start of the first MEX-CD1 treatment until the last visit, assessed up to 2 weeks.
Responder rate	The responder rate is defined as the proportion of patients with >50% of the baseline net amount of exchangeable copper extracted throughout the study.	4 hours; from treatment start (0 hours) to treatment end (4 hours)
Copper kinetics	Kinetics of Copper measurement at time 0h, time 1h, time 2h, time 3h and time 4h	4 hours; from treatment start (0 hours) to treatment end (4 hours)
Changes in copper concentration between screening visit and last visit	Assessment of the change in non-ceruloplasmin-bound copper (NCC) concentration between the baseline and the patient release	Between the screening visit and the last visit, assessed up to 2 weeks.
Hepatic function evolution	Assessment of the stability or improvement of hepatic function between the enrolment and the last visit of the patient according to the history of the disease. Hepatic function is assessed through medical imaging, transient elastography (FibroScan or FibroTest), LiverMultiScan™, assessment of presence/absence of jaundice, assessment of presence/absence of haemolysis, ascites detection per sonography.	Between the screening visit and the last visit, assessed up to 2 weeks.
Neurologic and psychiatric status evolution	Assessment of the stability or improvement of the neurological and psychiatric status between the enrolment and the last visit of the patient. Neurological and psychiatric status is evaluated with UWDRS scores, Clinical Global Impression-Improvement Scale (CGI-S versus CGI-I), MRI. (no units for all the scales)	Between the screening visit and the last visit, assessed up to 2 weeks.
Wilson's Disease evolution	Assessment of the stability or improvement of the WD by Global Assessment Scale for WD between the enrolment and the last visit of the patient.	Between the screening visit and the last visit, assessed up to 2 weeks.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
non-ceruloplasmin-bound copper elimination and restoration during the treatment	Assessment of the non-ceruloplasmin-bound copper elimination and restoration along the dialysis session.	4 hours; from treatment start (0 hours) to treatment end (4 hours)
non-ceruloplasmin-bound copper restoration between treatment	Assessment of the non-ceruloplasmin-bound copper restoration between dialysis sessions.	End of treatment session (n) to beginning of next treatment session (n+1), assessed up to 2 weeks.

Collaborators and Investigators

• Sponsor: Mexbrain
• Collaborators: Integrated Scientific Services (ISS) AG
• Investigators: Principal Investigator: Edouardo COUCHONNAL-BEDOYA, Hôpital Femme Mère Enfant, Service Hépato-Gastroentérologie et Nutrition Pédiatrique

Study record dates

Study Major Dates

• Study Start (Actual): January 24, 2024
• Primary Completion (Actual): September 15, 2025
• Study Completion (Actual): September 15, 2025

Study Registration Dates

• First Submitted: April 6, 2023
• First Submitted That Met QC Criteria: June 15, 2023
• First Posted (Actual): June 23, 2023

Study Record Updates

• Last Update Posted (Actual): December 5, 2025
• Last Update Submitted That Met QC Criteria: November 28, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: Wilson's Disease; Copper; Low-volume continuous veno-venous hemodialysis
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases; Digestive System Diseases; Neurodegenerative Diseases; Liver Diseases; Movement Disorders; Heredodegenerative Disorders, Nervous System; Basal Ganglia Diseases; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Metal Metabolism, Inborn Errors; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Hepatolenticular Degeneration
• Other Study ID Numbers: PJ2104-0003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No